Interesting Images68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies Has the Time Come to Remove “PS” From PSMA?Malik, Dharmender DNB*; Kumar, Rajender MD*; Mittal, Bhagwant Rai MD, DNB*; Singh, Harmandeep MD*; Bhattacharya, Anish MBBS, DNB*; Singh, Shrawan Kumar MS†Author Information From the Departments of *Nuclear Medicine and PET/CT, and †Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Received for publication February 11, 2018; revision accepted March 15, 2018. Conflicts of interest and sources of funding: none declared. Correspondence to: Rajender Kumar, MD, Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. E-mail: email@example.com. Clinical Nuclear Medicine: July 2018 - Volume 43 - Issue 7 - p 529-532 doi: 10.1097/RLU.0000000000002103 Buy Metrics Abstract PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) is increasingly recognized as the best imaging modality for disease staging and detection of recurrent prostate cancer. Despite its name, PSMA expression has been reported in a number of nonprostatic benign and malignant pathologies. Apparently, angioneogenesis is the mechanism attributed to increased 68Ga-PSMA uptake at these sites. Here we illustrate the utility of 68Ga-PSMA in 5 nonprostatic malignancies that could open up new possibilities for diagnostics and theranostic concepts with PSMA labeled radioligands in nonprostate tumor entities. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.